EUCTR2019-002911-25-PL进行中（未招募）1 期
Multicenter, Double-blind, Randomized, Parallel-group, Study Evaluating Pharmacokinetic, Efficacy, Safety, and Immunogenicity Between Patients with Moderate to Severe Chronic Plaque Psoriasis Receiving Humira® and Patients with Moderate to Severe Chronic Plaque Psoriasis Undergoing Repeated Switches Between Humira® and AVT02 Followed by a Safety Extension Phase of AVT02(ALVOPAD-X) - ALVOPAD X
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 548
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patient has signed the informed consent form and documentation as required by relevant competent authorities and is able to understand and adhere to the visit schedule and study requirements.
- •2. Patient is male or female aged 18 to 75 years, inclusive, at the time of Screening.
- •3. Patients with moderate-to-severe chronic plaque psoriasis who has involved body surface area (BSA) = 10% (Palm Method), = 12 on the PASI, and static Physicians Global Assessments (sPGA) = 3 (moderate) at Screening and at Baseline (Week 1/Day 1).
- •4. Patient has had stable disease for at least 2 months (ie, without significant changes as defined by the Investigator or designee).
- •5. Patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
- •6. Patient is naive to adalimumab therapy, approved or investigational.
- •7. Patient has a negative QuantiFERON test for tuberculosis (TB) during Screening.
- •Note: Patients with an indeterminate QuantiFERON test are allowed if they have all of the following:
- •a. No evidence of active TB on chest radiograph within 3 months prior to the first dose of study drug.
- •b. Documented history of treatment of TB or adequate prophylaxis initiation with an isoniazid-based regimen > 1 month prior to receiving study drug in accordance with local recommendations.
- •c. No known exposure to active TB after most recent prophylaxis.
- •d. Asymptomatic at Screening and Baseline.
- •Investigators should check with the medical monitor before enrolling such subjects.
- •8. Women of childbearing potential (except those who are postmenopausal for more than 2 years or if surgically sterile) must have a negative serum pregnancy test during Screening and negative urine pregnancy test at Baseline (Week 1/Day 1).
- •9. Sexually active women of childbearing potential must agree to use highly effective contraception (sterilization, hormonal contraception pills or injection or implants, sterilization and abstinence) for the duration of the study and until 6 months after the last dose of the study drug.
- •Male patients must agree to use contraception for the duration of the study and agree not to donate sperm during and for 6 months after the last dose of study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 500
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 48
排除标准
- •Exclusion Criteria:
- •1. Patient diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, other skin conditions (eg, eczema), or other systemic autoimmune disorder inflammatory disease at the time of the Screening visit that would interfere with evaluations of the effect of the study treatment of psoriasis.
- •2. Patient has prior use of any of the following medications within specified time periods or will require use during the study:
- •a. Topical medications within 2 weeks of Baseline (Week 1/Day 1).
- •b. PUVA phototherapy and/or UVB phototherapy within 4 weeks prior to the Baseline (Week 1/Day 1).
- •c. Nonbiologic psoriasis systemic therapies (eg, cyclosporine, methotrexate, and acitretin) within 4 weeks prior to the Baseline (Week 1/Day 1).
- •d. Any prior or concomitant adalimumab therapy, either approved or investigational.
- •e. Any systemic steroid in the 4 weeks prior to Screening.
- •f. Investigational agent(s) within 90 days or 5 half-lives (whichever is longer) before Baseline (Week 1/Day 1) (Refer to the table in protocol section 3.3.2 for approved/marketed products).
- •3. Patient has received live or attenuated vaccines during the 4 weeks prior to Screening or intends to receive a live or attenuated vaccine at any time during the study.
- •4. Patient has an underlying condition (including, but not limited to, metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious, or gastrointestinal) which, in the opinion of the Investigator or designee, significantly immunocompromises the subject and/or places the subject at unacceptable risk for receiving an immunomodulatory therapy.
- •5. Patient has a planned surgical intervention during the duration of the study and which, in the opinion of the Investigator or designee, will put the subject at further risk or hinder the patient’s ability to maintain compliance with study treatment and the visit schedule.
- •6. Has any active and serious infection or history of infections as follows:
- •a. Any active infection:
- •i. For which non-systemic anti-infective were used within 4 weeks prior to randomization. Note: patients receiving topical antibiotics for facial acne do not need to be excluded.
- •ii. Which required hospitalization or systemic anti-infective within 8 weeks prior to randomization.
- •b. Recurrent or chronic infections or other active infection that, in the opinion of the Investigator or designee, might cause this study to be detrimental to the subject.
- •c. Invasive fungal infection or mycobacterial infection.
- •d. Opportunistic infections, such as listeriosis, legionellosis, or pneumocystis.
- •7. Patient is positive for human immunodeficiency virus (HIV), hepatitis C virus (HCV) antibody, or hepatitis B surface antigen (HBsAg) and/or is positive for hepatitis B core antibody.
- •8. Patient has severe progressive or uncontrolled, clinically significant disease that in the judgment of the Investigator or designee renders the subject unsuitable for the study.
- •9. Patient has a history of malignancy within 5 years except for adequately treated cutaneous squamous or basal cell carcinoma, in situ cervical cancer, or in situ breast ductal carcinoma.
- •10. Patient has an active neurological disease, such as multiple sclerosis, Guillain-Barré syndrome, optic neuritis, and transverse myelitis, or a history of neurologic symptoms suggestive of central nervous system demyelinating disease.
- •11. Patient has moderate to severe heart failu
研究者
相似试验
进行中（未招募）
1 期
Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon ß 1a) in Patients with Relapsing-Remitting Multiple SclerosisRelapsing-remitting Multiple SclerosisMedDRA version: 12.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2009-012500-11-FRBiogen Idec Ltd1,841
进行中（未招募）
1 期
Comparison of Daclizumab HYP and Avonex® in Multiple SclerosisRelapsing-remitting Multiple SclerosisMedDRA version: 16.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-012500-11-GBBiogen Idec Ltd1,800
进行中（未招募）
不适用
Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex (Interferon ß-1a) in Patients with Relapsing Remitting Multiple Sclerosis - NDRelapsing Remitting Multiple SclerosisMedDRA version: 12.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2009-012500-11-ITBIOGEN IDEC LTD1,500
进行中（未招募）
不适用
Comparison of Daclizumab HYP and Avonex® in Multiple SclerosisRelapsing-remitting Multiple SclerosisMedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-012500-11-IEBiogen Idec Ltd1,800
进行中（未招募）
不适用
Comparison of Daclizumab HYP and Avonex® in Multiple SclerosisRelapsing-remitting Multiple SclerosisMedDRA version: 14.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-012500-11-HUBiogen Idec Ltd1,800